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SUPPLEMENT ARTICLE
Optimizing Clinical Trial Design to Maximize Evidence
Generation in Pediatric HIV
Deborah Ford, PhD,* Rebecca Turner, PhD,* Anna Turkova, MRCPCH,* Martina Penazzato, PhD,†
Victor Musiime, PhD,‡§ Mutsa Bwakura-Dangarembizi, MMed,║ Avy Violari, FCPaed(SA),¶
Chishala Chabala, MMed,#** Thanyawee Puthanakit, MD,†† Tavitiya Sudjaritruk, MD,‡‡§§
Tim R. Cressey, PhD,║║¶¶## Marc Lallemant, MD,║║¶¶ and Diana M. Gibb, MD*
Abstract: For HIV-infected children, formulation development,
pharmacokinetic (PK) data, and evaluation of early toxicity are critical
for licensing new antiretroviral drugs; direct evidence of efﬁcacy in
children may not be needed if acceptable safety and PK parameters are
demonstrated in children. However, it is important to address questions
where adult trial data cannot be extrapolated to children. In this fast-
moving area, interventions need to be tailored to resource-limited
settings where most HIV-infected children live and take account of
decreasing numbers of younger HIV-infected children after successful
prevention of mother-to-child HIV transmission. Innovative randomized
controlled trial (RCT) designs enable several questions relevant to
children’s treatment and care to be answered within the same study. We
reﬂect on key considerations, and, with examples, discuss the relative
merits of different RCT designs for addressing multiple scientiﬁc
questions including parallel multi-arm RCTs, factorial RCTs, and cross-
over RCTs. We discuss inclusion of several populations (eg, untreated
and pretreated children; children and adults) in “basket” trials;
incorporation of secondary randomizations after enrollment and use of
nested substudies (particularly PK and formulation acceptability) within
large RCTs. We review the literature on trial designs across other
disease areas in pediatrics and rare diseases and discuss their relevance
for addressing questions relevant to HIV-infected children; we provide
an example of a Bayesian trial design in prevention of mother-to-child
HIV transmission and consider this approach for future pediatric trials.
Finally, we discuss the relevance of these approaches to other areas, in
particular, childhood tuberculosis and hepatitis.
Key Words: clinical trial design, pediatric clinical trials, pediatric HIV
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BACKGROUND
HIV-infected children differ from adults in that they
acquire HIV around the time of birth when their immune
system is still developing; if untreated, they experience more
rapid disease progression and early mortality. Before ART
became available, half of HIV-infected African children died
before their second birthday.1 Conversely, children’s immune
systems have greater potential to recover than those of adults,
particularly if ART is started in early childhood.2
As in other diseases in children, availability of drugs lags
behind adults. It is now recognized by regulatory agencies that
when disease progression, drug response, and exposure response
in children are similar to adults, efﬁcacy can be extrapolated
from adult trials and only dose-ﬁnding and safety studies are
required for pediatric regulatory approvals.3–5 For these, the drug
in question (and age-appropriate formulations) should be
investigated across the entire age range because drug disposition
in children changes substantially with age.6 In contrast to
regulatory trials, strategy trials are used to evaluate different
treatment approaches (eg, sequence of regimens for ﬁrst-,
second-, third-line, treatment simpliﬁcation, and use of more
pragmatic dosing) and focus on effectiveness (ie, efﬁcacy in the
real world). Strategy trials often bridge the gap from the data
required for regulatory approval to the data needed to inform
clinical use and guideline development and are usually phase
III–IV randomized controlled trials (RCTs).
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In resource-limited settings, there are also program-
matic issues and costs, eg, it is difﬁcult for programs to
procure and maintain reliable supplies of a large number of
pediatric formulations, and liquid formulations are often
impractical. Effective and safe ﬁxed-dose combinations,
ideally as dispersible scored formulations, dosed according
to World Health Organization (WHO) weight-band tables, are
now widely recognized ideal for HIV-infected children.7 As
in adults, once-daily dosing is preferable for caregivers;
however, higher drug clearance in younger children can make
once-daily dosing a challenging pharmacokinetic (PK) goal.8
Limiting pill burden is also important, but it can be difﬁcult to
coformulate complex molecules in small-size scored pills that
can also allow for dose adjustments as children grow.
A recent paper by Penazzato et al9 discussed the
bottlenecks to rapid development of new antiretroviral drugs
and formulations for children and outlined some possible
solutions to streamline drug development studies seeking
regulatory approvals, including: (1) enrollment of adolescents
in adult trials; (2) simultaneous enrollment of children into
different age/weight bands in early PK studies; and (3)
optimized use of all available PK data and PK modeling.
We will complement this paper by focusing on designs for
large trials evaluating different treatment strategies.
Over the past 15 years, pediatric HIV RCTs have
played a major role in changing treatment guidelines and
leading to implementation of life-saving treatment and
clinical management for children living with HIV. In this
paper, we review the literature on types of trials that can
improve efﬁciency, minimize time and costs and, in turn, save
patient and health care resources.
OPTIMIZING TREATMENT FOR CHILDREN
Scientiﬁc questions about optimizing treatment for
children can take many forms, and will differ depending on
whether they are viewed from the vantage points of policy
maker, health care worker or family, and individual child or
young person. WHO and the Collaborative Initiative for
Paediatric HIV Education and Research (CIPHER) recently
used Child Health and Nutrition Research Initiative (CHNRI)
methodology for setting priorities in health research10 to
identify research gaps in pediatric and adolescent HIV from
a range of global stakeholders. The top priorities included
determining “the safety, efﬁcacy, acceptability, pharmacoki-
netics, and optimal dosing of existing and new antiretroviral
drugs and formulations for children,” improving adherence in
adolescents, and evaluating novel treatment delivery systems
in children and adolescents.11 Management and prevention of
coinfections, particularly tuberculosis (TB), viral hepatitis,
and bacterial infections, is another area where data in children
are largely limited to PK data on drug interactions.
All these questions would beneﬁt from more efﬁcient
study designs that can address multiple questions
while minimizing the number of patients enrolled.
DESIGNING EFFICIENT TRIALS
Below, we describe trial designs for pediatric HIV that
illustrate how several questions can be addressed within a single
trial. Most are relatively long-term trials and include added-value
PK, basic science, and social science substudies (Table 1).
Parallel Two-Arm RCT
The Children with HIV Antibiotic Prophylaxis (CHAP)
trial (2001–2003) was a classic double-blind randomized
placebo-controlled trial in HIV-infected Zambian children.12
Five hundred forty-one children aged 1–14 years were
randomized to cotrimoxazole prophylaxis or placebo (before
available ART provision). The trial was stopped early
because of a 43% reduction in mortality in the cotrimoxazole
group and was followed by WHO guidelines recommending
cotrimoxazole for all HIV-infected or exposed African
children unless absence of HIV infection was demonstrated.13
The Thai PREDICT trial (2006–2011) also used
a parallel randomized 2-arm design to compare early with
deferred ART in children with CD4 percentage $15%.14 By
necessity, PREDICT was “open-label,” with no placebo;
although this is pragmatic and avoids unreal adherence, the
issue of bias in such trials has to be considered when
interpreting reporting of clinical endpoints.
Parallel Multi-Arm RCT
Multi-arm trials offer advantages over 2-arm trials.
They allow for more candidate treatments to be tested
simultaneously and increase chances of ﬁnding an effective
treatment in a shorter time frame.15 They are often more cost-
effective than evaluating the same interventions in several 2-
arm trials, by reducing the number of control patients needed
and the administrative costs. Multiple hypotheses are tested
within such trials; so, a well-deﬁned analysis plan and
appropriately estimated sample size are essential. A common
approach is to power a multi-arm trial based on one global
test across all treatment arms (usually of any difference
between arms); only if this is signiﬁcant, other comparisons
are tested.16,17
The Children with HIV Early Antiretroviral Therapy
(CHER) trial in South Africa was an open-label 3-arm RCT in
411 HIV-infected asymptomatic infants younger than 12
weeks recruited 2005–2007. Infants were randomized to
deferred ART, immediate ART for 40 weeks (and then stop),
or immediate ART for 96 weeks (and then stop) (Fig. 1A).
ART was initiated in the deferred arm or restarted in the early
treatment arms based on CD4 or clinical criteria.18,19 At the
time of the trial, standard-of-care was deferred ART; the trial
hypothesis was that early time-limited ART would be safe
and provide long-term beneﬁt by delaying immunological and
clinical disease progression when compared with deferred
ART. There was uncertainty around the optimal duration of
early limited ART, with the possibility that 2 rather than 1
year of ART might allow for better development of the
immune system, counterbalanced by increased risk of resis-
tant virus with longer initial ART duration. A 3-arm trial
allowed for both strategies to be evaluated together. The
planned primary analysis was to test the null hypothesis of no
difference among the 3 arms in time to death or treatment
failure and only if the null hypothesis were rejected, to
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TABLE 1. Advantages and Disadvantages of Different Trial Designs
Design Advantages Disadvantages Examples
Two-arm Simplest design logistically Only 2 treatments are compared CHAP12
Interpretation of results is
straightforward
Other designs may offer greater
efﬁciency in overall resource use
PREDICT14
Multi-arm Reduced administrative costs in
comparison with multiple separate 2-
arm trials
Accrual within arms may be slow CHER18,19
CHAPAS-321
Fewer patients required overall
Crossover individual randomised trial Can compare 2 or more interventions;
randomise the order they are given
Fewer patients as variability within child
is lower than between child
Useful for early trials comparing short-
term effects of interventions, different
PK doses and drug formulations
Cannot be used if intervention has
a longterm effect, although a wash-out
period may be included
Requires strict adherence to follow-up to
prevent loss of comparator data if
individual patient drops-out
CHAPAS 238,39
Factorial Efﬁcient evaluation of multiple
treatments
Can evaluate interaction between
treatments (if powered to detect this)
Difﬁculties interpreting main treatment
effects if an interaction exists
May be complex to report if both
randomisations are reported together
ARROW22
PENPACT-124
REALITY26
Basket Evaluate an intervention in more than
one population (each fully powered)
Accrual within different patient cohorts
may differ
P106030–32
ODYSSEY34
Efﬁcient use of resources
Adaptive Trial design can change in response to
interim analysis or external
information
Efﬁcient use of resources
Logistically complex
Allowance must be made for multiple
testing, in order that type I error is
controlled
Sample sizes can be recalculated to avoid
an expected lack of power
Higher probability of ﬁnding an
effective treatment, in comparison
with static design
Interim analysis results are highly
variable, so could mislead redesign of
the trial
Multi-arm multi-stage (MAMS) New treatments of interest can be
incorporated into the ongoing trial
Efﬁcient use of resources
Higher probability of ﬁnding an effective
treatment, in comparison with static
design
Improved recruitment in later treatment
arms
Logistically complex
Allowance must be made for multiple
testing, in order that type I error is
controlled
Accrual within arms may be slow
Cluster randomised May be necessary for evaluating
community interventions (eg, health
promotion programme)
Administrative convenience
Preventing “contamination” between
patients in the same cluster
Sample size required may be
substantially higher than in an
individually randomised design
Potential for selection bias (differing
recruitment in treatment/control arms)
Potential for imbalance on confounders
between trial arms (if number of
clusters is small)
Multi-component community based
adherence program to improve
adherence and retention in care among
adolescents on ART44
Bayesian design incorporating external
data (eg, using adult data to inform
a paediatric trial)
Sample size required can be reduced by
“borrowing information” from
a relevant external trial(s)
Requires clinical judgement about the
relevance of the external data to the
child population
PHPT-5 second phase
(PMTCT trial)49–52
Efﬁcient use of resources
May be the only ethically acceptable
approach
Potential for bias and increased type I
error if external data and new trial data
give conﬂicting results
For rare diseases may be the only
feasible approach
Advantages and disadvantages are unrelated.
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compare each of the early treatment arms to the deferred arm.
Based on early CHER results,18 the data monitoring commit-
tee recommended that enrollment to the deferred arm be
stopped, and children in that arm were evaluated for need to
start ART; the other 2 arms continued enrollment. Publication
of these early ﬁndings resulted in WHO recommending
immediate treatment for all infants with conﬁrmed HIV
infection in 2008.20 The trial continued over 5 years, and
demonstrated sustained beneﬁt of early ART with both
experimental arms performing better than deferred ART and
a nonsigniﬁcant trend toward better outcomes with 96 weeks
compared with 40 weeks of ART.19
The CHAPAS-3 trial in Zambia and Uganda (2010–
2014) was another 3-arm trial, powered for a toxicity primary
endpoint comparing 3 nucleoside backbones in both ART-
naive and virologically suppressed children on stavudine-
based ﬁrst-line ART (Fig. 1B).21
Factorial RCT
A factorial trial simultaneously allows for 2 (or more)
interventions, preferably targeting different aspects of a pa-
tient’s disease, to be compared with standard treatment(s).
ARROW (AntiRetroviral Research fOr Watoto) was a facto-
rial trial evaluating 2 approaches for management of ART in
1200 symptomatic HIV-infected infants and children starting
ART between 2007 and 2008 in Uganda and Zimbabwe. The
ﬁrst strategy compared clinically driven monitoring with
routine laboratory monitoring plus clinical monitoring. The
second strategy compared 3 different ART regimens (Fig.
2A).22 Children were randomized to both strategies at trial
entry; thus, all 6 combinations (2 monitoring strategies · 3
regimens) were equally likely. As is common for factorial
trials, at the design stage, separate sample size calculations
were performed based on target effect sizes for the 2 strategies
(using a noninferiority comparison for WHO 4 events/death
for the monitoring arm comparisons and a global test of
change in CD4% across the 3 ART regimens for the second
strategy), with the larger of the 2 sample sizes taken
forward.22,23 Critically, a factorial design usually assumes
no interaction between interventions and, provided this is the
case, signiﬁcantly fewer patients are required than for
a parallel multi-arm trial.23 In ARROW, although the
predeﬁned noninferiority criterion for clinically driven mon-
itoring versus laboratory and clinical monitoring was met,
CD4 monitoring provided a small clinical beneﬁt after the
ﬁrst year on ART. Mean CD4 percentage did not differ
between ART groups at weeks 72 or 144, although at week
36, participants on 4-drug regimens did better on average.22
PENPACT-1 was a collaborative 2 · 2 factorial trial
sponsored jointly by the Paediatric European Network for
Treatment of AIDS (PENTA) Foundation, Agènce Nationale
de Recherche sur le Sida (ANRS), and the Pediatric AIDS
Clinical Trials Group (PACTG), subsequently the Interna-
tional Maternal Pediatric Adolescent AIDS Clinical Trials
(IMPAACT). Children initiating ART between 2002 and
2005 were simultaneously randomized to ART regimen
(nonnucleoside reverse transcriptase inhibitor versus protease
inhibitor + 2 nucleoside reverse transcriptase inhibitors) and
to viral load threshold (1000 versus 30,000 copies/mL) for
switch from ﬁrst-line to second-line ART (Fig. 2B).24 Good
long-term virological outcomes were achieved across the trial
with no difference in mean viral load changes from baseline
to 4 years by ART regimen or by switch threshold. The trial
was not powered to detect interactions between regimen and
switch threshold; however, for nucleoside reverse transcrip-
tase inhibitor resistance, an interaction was observed with
more major mutations in the group starting on a nonnucleoside
FIGURE 1. Parallel 3-arm RCTs: (A) CHER trial and
(B) CHAPAS-3 trial.
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reverse transcriptase inhibitor and switching to second-line at
30,000 copies per milliliter.
The recently completed REduction of Early mortaLITY
(REALITY) trial included both HIV-infected adults and children
aged 5 years and older (who have similar risks of disease
progression by CD4 value after starting ART25) and was a 2 · 2
· 2 factorial trial (3 randomizations) evaluating 3 unrelated
strategies to reduce mortality in patients starting ART with
severe immunodeﬁciency in Africa.26 REALITY recruited only
72 children of 1805 patients with CD4 ,100 cells/mm3, lower
than expected because few children were found with CD4,100
and adults recruited more quickly than anticipated.
Secondary Randomizations After Enrollment
Another way to answer additional questions is to include
secondary randomization(s) after enrollment, as in the ARROW
trial. Children taking lamivudine and abacavir (3TC + ABC)
containing ﬁrst-line regimens were randomized after 36 weeks to
continue twice-daily versus switching to once-daily 3TC
+ABC27; in addition, children older than 3 years were
randomized after 96 weeks to stop or to continue cotrimoxazole
prophylaxis (Fig. 1A).28 Both randomizations were stratiﬁed by
the 2 baseline factorial randomizations (described above). In this
way, in addition to answering the original trial questions,
ARROW also provided evidence for the ﬁrst once-daily
nucleoside backbone for children27 and for continued use of
cotrimoxazole prophylaxis in children on ART.28
Basket Trial
A basket trial includes 2 or more well-deﬁned cohorts
in which the same intervention is tested; the trial is
powered to evaluate the intervention within each cohort.29
Efﬁciency is gained by simultaneous recruitment of the
cohorts at the same clinical trial sites. The IMPAACT
P1060 trial compared nevirapine with lopinavir/ritonavir
(LPV/r) for ﬁrst-line treatment in children younger than 3
years in Africa and India. Two cohorts were enrolled:
cohort I included children with previous exposure to
single-dose nevirapine for prophylaxis30; cohort II children
had no previous nevirapine exposure.31 P1060 had a com-
posite endpoint including both clinical progression and
viral load response at 24 weeks. Recruitment to cohort I
stopped early because results showed superiority of LPV/
r30; cohort II completed planned enrollment and follow-up
to 24 weeks and also demonstrated superiority of LPV/r31;
follow-up continued for 5 years.32 WHO guidelines were
changed in 2013.33
FIGURE 2. Factorial RCTs: (A) ARROW trial (B)
PENPACT-1 trial.
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The ongoing ODYSSEY trial is also a basket trial
including 2 individually powered, randomized phase III trials
in ART-naive children and children failing ﬁrst-line ART.
Children are stratiﬁed based on ART history and
then randomized to dolutegravir-based ART versus
standard-of-care.34
Adaptive RCT
The protocol for an adaptive trial prespeciﬁes param-
eters (eg, dose, sample size, treatment, and patient selection
criteria) that may be modiﬁed during the trial and the process
for modiﬁcation.35 Changes are planned and made “by
design” preserving the statistical validity and integrity of
the trial.29,36 Use of adaptive designs can lead to smaller
sample sizes and increases chances of ﬁnding an effective
treatment. The Multi-Arm Multi-Stage (MAMS) RCT is
a particular type of adaptive trial in which the multi-arm
element involves comparing several interventions simulta-
neously against a common control group; the multistage
element requires patient recruitment to research arms that are
not showing sufﬁcient beneﬁt to be discontinued, based on
a series of preplanned, interim, futility analyses. It also allows
for introduction of new research arms.29,37 MAMS trials may
be appropriate where there are multiple drugs to be tested and
where a surrogate short-term endpoint can be used to assess
the likelihood of treatment success. MAMS trials have not, to
the best of our knowledge, been used in pediatric populations,
likely because most new drugs are initially evaluated in
adults. They have also not been used in HIV, where long-term
outcomes are usually required to assess efﬁcacy.
Individual Cross-Over Trial
A cross-over trial compares 2 interventions with each
patient receiving both (the order of the interventions may be
assigned at random) and is often more efﬁcient than a parallel
group trial because patient variation is removed from the
treatment comparison. However, implementation is limited to
considering short-term treatment effects on chronic conditions
where it is appropriate for patients to receive both treatments.
CHAPAS-2 compared PK and acceptability of different
formulations of LPV/r in a cross-over trial of HIV-infected
infants and children in Africa.38,39 In a 2-period cross-over
design, children aged 3 months to 13 years had 4 weeks on
one formulation of LPV/r and then switched to an alternative
formulation. Order of formulation was randomized in the
older age groups (Fig. 3). LPV/r exposure from minitabs was
comparable with syrups but lower than from tablets.38
Follow-up to 12 months showed that preference
FIGURE 3. Individual cross-over trial: CHAPAS-2 trial.
FIGURE 4. Bayesian trial design: PHPT-5
second phase.
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for minitabs in younger children waned over time due to taste,
although they were easier to store and transport than syrup.39
Cluster RCTs
Cluster RCTs are used where the intervention is
naturally applied to a group or cluster (eg, community, health
centre, or school) and/or where individual randomization
could result in contamination between the comparison groups
(eg, sharing of medications in a household or learning about
and implementing an experimental health prevention strategy
in the control arm). Disadvantages are that a large sample size
is usually required and there is a risk of selection bias if
recruitment patterns differ systematically between treatment
arms.40,41
Cluster RCTs are particularly helpful when investigat-
ing the impact of novel service delivery interventions, eg, to
evaluate support strategies for women starting ART during
pregnancy or breastfeeding (Option B+).42,43 An ongoing
cluster RCT in Zimbabwe is evaluating a multicomponent
community-based intervention to improve adherence to ART
and retention in care of adolescents.44 A cluster RCT design
is less likely to be appropriate for evaluating treatment for
disease where the unit of intervention is the individual.
Nested Substudies
Substudies can add signiﬁcant value to a trial. The
ongoing ODYSSEY trial34 includes 3 dolutegravir PK
substudies: ﬁrst, in children weighing less than 25 kg, which
will complement the regulatory dose-ﬁnding study(IM-
PAACT P1093)45; second, in children weighing 25–40 kg,
PK on both current recommended dolutegravir doses and
after an increase to the adult dose of dolutegravir (also
allowing for alignment with current ABC/3 TC ﬁxed-dose
combination); and third, dolutegravir and rifampicin PK in
children with TB. There is also an immunology/virology
substudy, a social science substudy, and a project to establish
Youth Trial Boards to develop a model for adolescent patient
representation in pediatric clinical trials.
WHAT OTHER DESIGNS COULD BE CONSID-
ERED FOR HIV-INFECTED CHILDREN?
Given decreasing numbers of vertically HIV-infected
children globally, it is useful to consider trial designs used in
rare and/or other pediatric diseases. Baiardi reviewed inno-
vative designs for clinical trials in children, focusing on
overcoming difﬁculties related to small sample sizes and
ethical concerns46; other authors have proposed algorithms
for choosing between different trial designs when researching
rare diseases.47,48 An example is a recent trial of drugs for
preventing intrapartum mother-to-child-transmission of HIV
in Thailand that used a Bayesian approach to trial design.49–52
The trial’s objective was to evaluate the efﬁcacy of anti-
retroviral intensiﬁcation, ie, adding maternal nevirapine
during labor and infant triple ART prophylaxis in addition
to standard-of-care in mothers presenting late in pregnancy.
Design issues included ethical concerns about providing
placebo where infants were at high risk and low numbers of
mothers presenting late in the Thai context. Historical data
from 3965 mother–infant pairs (enrolled in 3 previous ran-
domized trials conducted in the same setting49,53,54) were
used to build a model to generate prior distributions of in-
trapartum transmission probabilities with/without anti-
retroviral intensiﬁcation. These probabilities were
subsequently updated using results of a single-arm trial where
88 mothers and high-risk children received antiretroviral
intensiﬁcation; no transmission was observed (Fig. 4). The
posterior probability of intrapartum transmission was 0.39%
(95% CI 0.12–1.4) with intensiﬁcation compared with 2.0%
(0.3–5.2) without. The probability of superiority of intensi-
ﬁcation over standard-of-care (RR ,1) was 0.94 and
probability of at least 2-fold reduction of risk (RR ,0.5)
was 0.83. When solid historical data are available and
equipoise cannot be assumed, a Bayesian design can provide
conﬁrmation where a standard design would not
be appropriate.
In a similar way, a Bayesian design incorporating adult
data could be useful for trials in HIV-infected children: by
“borrowing information” from the evidence available in
a completed adult trial and incorporating clinical judgment
about the relevance of the adult data to the pediatric
population; in this way, the sample size required in a pediatric
trial could be reduced.55–58
OTHER PEDIATRIC INFECTIONS
Coinfections with diseases such as TB, hepatitis, and
bacterial infections occur in pediatric HIV and management
of these children has generally been extrapolated from adults.
Where logistically possible and scientiﬁcally appropriate,
consideration should be given to including adults and older
children and adolescents in trials together. Opportunities for
PK substudies to evaluate drug–drug interactions in coin-
fected children within large pediatric trials are efﬁcient and of
low cost and should be encouraged.
As for HIV, scientiﬁc questions requiring larger trials in
children with other diseases should be based on examining
ways in which the disease differs in children compared
with adults.
TB in children is paucibacillary in nature and unlike in
adults, nonsevere forms predominate. Thus, although adult
trials of treatment shortening have so far not been successful,
this approach may be more likely to succeed in children with
mild disease. The ongoing SHINE trial is a parallel 2-arm
RCT comparing 4-month treatment with 6-month treatment in
1200 HIV-infected and HIV-uninfected children with non-
severe TB and will inform whether treatment shortening of
drug-susceptible TB is efﬁcacious and safe in this popula-
tion59; it will also ﬁll existing gaps in knowledge on dosing of
new anti-TB formulations and commonly used HIV drugs.
Pediatric hepatitis C (HCV) has been neglected and
there are no direct acting anti-HCV (DAA) drug regimens
available for young HCV-infected children. The rapid
development of multiple new drugs for adults from a number
of innovator companies has meant that submitted pediatric
investigation plans rapidly become out of date and very little
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has been realized in terms of evaluating age-appropriate
formulations and dosing data of DAAs for children. To date,
only 2 DAAs have been approved for adolescents aged 12
years and older.60,61 Now that several safe short regimens are
available to cure the disease in adults, single-arm PK studies
with safety data could be rapidly completed for the lead
DAAs using a common protocol. However, an opportunity
was lost to undertake an earlier adaptive trial comparing
DAAs head-to-head in children, possibly including Bayesian
approaches incorporating adult data as they became available.
Design of trials in TB, HCV, and hepatitis B has been
complicated by difﬁculties with diagnosis: TB diagnosis is
often presumptive and hepatitis C infection may clear in
young children, making clinicians reluctant to treat before the
third year of life. Hepatitis B, which is common (6%–10%) in
Africa,62 may be more often acquired horizontally in child-
hood, and point-of-care E-antigen diagnostics, although under
development, are not yet available. However, with the
development of tenofovir alafenamide for HIV treatment,
which is also an effective drug against hepatitis B, there may
be opportunity to jointly evaluate tenofovir alafenamide for
both diseases within the same trial in the future.
CONCLUSIONS
Global research priorities for children and adolescents
living with HIV highlight the remaining evidence gaps and
the need to ensure that high-quality evidence is generated to
inform clinical practice and global policies. This need, in the
context of the changing epidemiology and decreasing resour-
ces, requires that innovative but rigorous trial designs are
used when investigating key research questions. In this study,
we have focused on describing the main types of trial designs
for larger RCTs, with particular emphasis on increasing
efﬁciency by addressing multiple scientiﬁc questions that
cannot be extrapolated from adult trials. We have used
examples of pediatric HIV trials to also demonstrate the
value of embedded substudies and highlighted how similar
principles should be used in designing trials in other
infectious diseases in children and adolescents. Efforts should
be made to ensure that innovative and efﬁcient trial designs
are funded. Combining innovation and capacity building will
be the key to undertake high-impact research that will take us
closer to reach treatment targets for children and adolescents
living with HIV and other infections.
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